Study Summaries
Study summaries are free for everyone to read. Requires registration for free account of GYOEDU
💡
The information provided on this website is intended for general informational purposes only and should not be considered medical advice. While we strive to ensure the content is accurate and up-to-date, Gyoedu LLC does not guarantee the information's correctness, completeness, or timeliness. Users are encouraged to independently verify any information found on this site.
Cervical Cancer
-
Early Disease
-
Sentinel Lymph Nodes
-
Locally Advanced Disease
- EORTC-55994: Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer
- UTERUS-11:Surgical versus clinical staging before primary chemoradiation
- Tata Memorial Hospital Trial: Neoadjuvant Chemo + Rad Hyst Vs. Standard ChemoRT
- OUTBACK Trial: Chemotherapy after Chemoradiation
- KEYNOTE A18: Pembrolizumab Plus Chemoradiotherapy for High-Risk Locally Advanced Cervical Cancer
- CALLA: Durvalumab versus placebo with chemoradiotherapy
- Interlace Trial: Induction Chemotherapy prior to Chemoradition for Locally Advanced Cervical Cancer
-
Recurrent/Metastatic Disease
- GOG 240: Bevacizumab in Cervical Cancer
- Tisotumab in Cervical Cancer: InnovaTV 204/ GOG-3023/ENGOT-cx6 Phase 2 trial
- Tisotumab in Cervical Cancer: InnovaTV 301/ENGOT-cx12/GOG-3057 Phase 3 trial
- Immunotherapy Trials
- BEATcc: Atezolizumab added to Cis/Taxol/Bev in recurrent/metastatic cervical cancer
- KEYNOTE-826: Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
- COMPASSION 16: Cadonilimab for persistent, recurrent, or metastatic cervical cancer
- CHECKMATE 0358-Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer
Endometrial Cancer
-
Surgical Trials
-
High-Risk
- PORTEC 1: EBRT vs. Observation in Endometrial Cancer
- GOG 249: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer
- PORTEC 2: Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk
- Keynote B-21: Pembrolizumab vs. Placebo in High-risk Endometrial Cancer
-
Advanced/Recurrent Disease
- GOG 122:RT vs. Chemo in Endometrial Cancer
- GOG 209: Carboplatin and Paclitaxel for Advanced Endometrial Cancer
- GOG 238: Radiation With or Without Cisplatin in Locally Recurrent Endometrial Cancer
- GOG 258: Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
- PORTEC 3: Adjuvant chemotherapy vs. radiotherapy in high-risk endometrial cancer
- GOG 261: Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Carcinosarcoma
- NRG-GY012: Olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer
- SIENDO Trial: Selinexor in TP53wt Advanced or Recurrent Endometrial Cancer
- Immunotherapy Trials
- Upfront therapy
- Recurrence
-
Hormonal/Targeted Therapy Trials
Ovarian Cancer
-
Early Stage Disease
-
Surgical trials
-
Upfront treatment trial
-
Dose-Dense therapy trials
-
Intraperitoneal therapy and HIPEC trials
- GOG 172: IP chemotherapy
- GOG 252: Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma
- OV-HIPEC 1: Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
- Korean HIPEC trial
- Korean HIPEC trial - IDS only 2023
- CHIPOR Trial: Secondary Debulking and HIPEC in PSOC
-
PARP Maintenance Trials
-
Bevacizumab Trials
- GOG 218 (coming soon)
- ICON 7 (coming soon)
-
Recurrent treatment trials
- Platinum-Sensitive Disease
- Platinum-Resistant Disease
-
Bevacizumab Trials
-
Low-Grade Ovarian
-
Mucinous Ovarian Cancer
Vulvar Cancer
- Sentinel Nodes
- Locally Advanced Disease
Sarcoma
- GOG 277: Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma
- GeDDiS Trial: Gemcitabine and docetaxel versus doxorubicin as first-line treatment sarcomas
- LMS-04: Doxorubicin alone versus doxorubicin with trabectedin for metastatic or unresectable leiomyosarcoma
Old Study Summaries
To access old study summaries submitted by volunteers, click here: